# Operational Increment 21 — Acceptance

Status: **Satisfied**

Change authority: `docs/change-control/CR-001-AMENDMENT-18-ENTERPRISE-MODEL.md`

## Evidence

- [x] The protected endpoint requires governed identity, contextualization permission, exact registration/run/object/fingerprint/evidence references, purpose, classification, and environment.
- [x] Signed OPA authorization is validated before registration receipt, delivery-run, or Enterprise Model reads.
- [x] The Automatic Registration receipt must be accepted, exact, evidence-bearing, non-advancing, and confirm atomic Enterprise Object persistence.
- [x] The deterministic delivery run must be stopped exactly at `DeliveryStage.AutomaticRegistration` with complete ordered evidence.
- [x] The authorized registered object exactly matches its registration identity, tenant, source, state, lifecycle, classification, policies, actions, timestamps, and evidence.
- [x] Every included relationship remains explicit and evidence-bearing.
- [x] Result authorization and cryptographic evidence precede contextualization receipt release.
- [x] No additional model mutation, unbounded traversal, impact analysis, simulation, inference, action, workflow advancement, or Evidence completion is available.
- [x] All six new Enterprise Model contextualization dependencies remain unregistered and fail closed before reads.
- [x] OpenAPI 3.1 and Blazor communicate the exact boundary without claiming configured readiness.
- [x] Anonymous access returns a bearer challenge.
- [x] All prior phase and Increment 01–20 gates remain satisfied.
- [x] All 15 projects build with zero warnings and zero errors.
- [x] Runtime verification proves the protected endpoint and all 136 required runtime dependencies remain fail closed.

## Result

Operational Increment 21 is complete. The exact registered service can be confirmed only through OPA-authorized Enterprise Model access after accepted Automatic Registration and a deterministic run at `AutomaticRegistration`. The registered object and its institutional controls are revalidated and independently authorized and evidenced. No additional mutation or later capability is introduced; Evidence completion remains the sole remaining station.
